Drug intelligence / Profile preview

RO5011232

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RO5011232 is a small molecule compound developed as a radiotracer for positron emission tomography (PET) imaging of the metabotropic glutamate receptor 5 (mGluR5) in the brain. The [11C]-labeled version ([11C]RO-5011232) has been used in clinical studies to assess mGluR5 receptor occupancy and distribution. It acts as an mGluR5 modulator and was primarily investigated for its utility in neuroimaging rather than direct therapeutic intervention. The compound was developed by F. Hoffmann-La Roche Ltd.[3]

Other names: Bitopertin (note: Bitopertin is a related glycine reuptake inhibitor, but in this context, RO5011232 refers specifically to the radiolabeled compound used as a PET tracer)

Targets

GRM5 (Metabotropic glutamate receptor 5)

Beyond the preview

Go deeper on RO5011232.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5011232.

Explore the full profile